Stock 4543 TERUMO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Terumo Corporation

Equities

4543

JP3546800008

Delayed Japan Exchange
Other stock markets
 09:22:41 2024-04-18 pm EDT 		5-day change 1st Jan Change
2,547 JPY -1.07% Intraday chart for Terumo Corporation -2.81% +10.13%
Apr. 12 Penumbra, Inc. : The underdog in healthcare Our Logo
Mar. 18 Frontier Field Co., Ltd. announced that it has received funding from Terumo Corporation CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With an expected P/E ratio at 35.77 and 30.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 4.29 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
TERUMO CORPORATION Stock Terumo Corporation
+11.40% 24.93B
A-
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.36% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.87% 105B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.38% 67.09B
A
DEXCOM, INC. Stock DexCom, Inc.
+8.23% 51.61B
B-
CENCORA, INC. Stock Cencora, Inc.
+15.54% 47.55B
B-
HOYA CORPORATION Stock Hoya Corporation
+0.60% 39.95B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+7.16% 27.62B
A-
SARTORIUS STEDIM BIOTECH Stock Sartorius Stedim Biotech
-12.48% 25.74B
B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
-1.68% 25.62B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4543 Stock
  4. Ratings Terumo Corporation